Hypertension Chronic kidney disease
Conditions
Interventions
ACE inhibitor group: Patients are initially given 2.5 mg of benazepril once daily for 24 weeks. The dosse of benazepril can be titrated up to 10 mg daily as needed.
Direct renin inhibitor group: Patie
Sponsors
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hypertensive patients with chronic kidney disease who are already receiving standard doses of AT1 receptor blocker but without achievement of blood pressure lowering to target blood pressure levels.
Exclusion criteria
Exclusion criteria: 1. Dialysis patients 2. Patients with history of angioedema 3. Patients on apheresis therapy 4. Patients taking cyclosporin 5. History of hypersensitivity to benazepril and/or aliskiren 6. Pregnant women and/or women who are suspect of pregnancy 7. Patients judged as inappropriate for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Blood pressure (clinical BP, ABPM) 2. Renal function (s-Cr, eGFR, urinary protein/albumin excretion) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Glucose metabolism (FBS, HbA1C, IRI, HOMA-IR) 2. Lipid metabolism (TCHO, LDLC, HDLC, TG) 3. Sympathetic nerve activity, renin-angiotensin system (PRA, PAC, catecholamine, urinary AGT) 4. Oxidative stress (urinary L-FABP, serum pentosidine) 5. Cardiovascular function (BNP, UCG, PWV, central blood pressure) 6. Adverse events | — |
Countries
Japan
Contacts
Public ContactKouichi TAMURA
Yokohama City University School of Medicine Department of Cardiorenal Medicine
Outcome results
None listed